Form 4: Neumora Therapeutics Director Receives Repriced Stock Options and New Grant Following Shareholder Approval

A director at Neumora Therapeutics, Inc. has received repriced stock options and a new option grant, approved by shareholders, adjusting exercise prices to incentivize future performance.

Summary

• Alaa Halawa, a Director of Neumora Therapeutics, Inc. (NMRA), reported changes in beneficial ownership of derivative securities on May 28, 2025.
• The company's stockholders approved the repricing of outstanding stock options held by Board members, certain employees, and other service providers.
• Two existing stock options with an exercise price of $1.69 per share, covering 46,455 and 28,571 shares respectively, were effectively disposed of and immediately re-acquired at a repriced exercise price of $0.72 per share.
• The repriced option for 46,455 shares (originally granted September 14, 2023) vests 1/36th monthly, becoming fully vested on its third anniversary (September 14, 2026).
• The repriced option for 28,571 shares is fully vested and exercisable.
• A new stock option grant for 80,000 shares was also issued to Alaa Halawa with an exercise price of $0.72 per share.
• The 80,000 share option vests 100% on the earlier of May 28, 2026 (one-year anniversary) or immediately prior to the next Annual Meeting following May 28, 2025.
• The repricing is contingent on the Reporting Person remaining in service to the Issuer through August 13, 2026.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the underlying reason for repricing (past stock underperformance), but it's mitigated by the positive aspect of re-incentivizing a key director and shareholder approval, which could lead to future positive outcomes.

Positives

• The repricing of stock options at a significantly lower exercise price ($0.72 from $1.69) provides a renewed incentive for the director and other key personnel, aligning their interests with potential future stock price appreciation.
• The grant of an additional 80,000 stock options further strengthens the director's incentive to contribute to the company's long-term success.
• Shareholder approval of the repricing indicates alignment between the company's board and its investors regarding executive compensation strategy.

Negatives

• The need for option repricing typically suggests that the company's stock price has significantly underperformed since the original options were granted, indicating past challenges or a decline in market valuation.
• Repricing can be viewed negatively by some shareholders as it effectively lowers the performance hurdle for executives to realize value from their equity awards, potentially diluting existing shareholder value if not justified by strategic necessity.

Risks

• The repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026; failure to meet this condition would negate the repricing benefit for those specific options.
• Future stock price performance may not reach levels that make the repriced options significantly in-the-money, despite the lower exercise price.

Future Outlook

The repricing and new option grant indicate the company's strategy to re-incentivize its leadership following a period where the stock price likely declined. This move aims to align management's financial interests with a future recovery and growth in shareholder value, contingent on continued service.

Management Comments

• On May 28, 2025, the Issuer's stockholders approved the repricing of the option.
• The repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Industry Context

Stock option repricing is a mechanism often employed by companies, particularly in sectors like biotechnology or pharmaceuticals, when their stock price has significantly declined below the exercise price of previously granted options. This is done to restore the incentive value of equity awards for key personnel, preventing them from becoming 'underwater' and thus ineffective as retention or performance tools. It reflects a need to re-motivate management in challenging market conditions or after a period of underperformance.

Comparison to Industry Standards

• While specific comparable companies are not named in the filing, option repricing is a common practice in the biotech and pharmaceutical industries, especially for early-stage or growth companies that may experience significant stock price volatility.
• The reduction from $1.69 to $0.72 represents a substantial repricing, indicating a significant decline in the company's stock value since the original grants, which is not uncommon for companies in volatile sectors that have faced setbacks or market downturns.
• The inclusion of a service condition (through August 13, 2026) for the repriced options is a standard corporate governance practice to ensure continued commitment from the incentivized individual.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution if options are exercised, but also potential for improved company performance due to re-incentivized management. The repricing itself indicates past stock underperformance.
• Directors/Employees: Direct benefit through lower exercise prices on existing options and new grants, providing renewed incentive and potential for future financial gain.

Next Steps

• Alaa Halawa's continued service to Neumora Therapeutics, Inc. through August 13, 2026, to ensure the effectiveness of the repriced options.
• Vesting of the 46,455 repriced shares over the next year, completing by September 14, 2026.
• Vesting of the 80,000 newly granted shares by May 28, 2026, or prior to the next Annual Meeting.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Form 4, stock options, option repricing, director compensation, equity incentives, insider transaction, corporate governance, vesting schedule